Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Ascorbate Deficiency Is Associated with Severity of Cytokine Release Syndrome Following Therapy with Chimeric Antigen Receptor T-Cells

Blood (2021) 138 (Supplement 1): 4801.

https://doi.org/10.1182/blood-2021-153929

Published: 2021

Journal Articles

T-Cell Telomere Length As a Biomarker to Predict Outcome in Patients Receiving CAR-T Immunotherapy

Enzo Tedone, Mohammed Sayed, Tsung-Po Lai, Aishwarya Sannareddy, Dheepthi P. Ramasamy, Larry D. Anderson, Jr., Farrukh T. Awan, Gurbakhash Kaur, Stephen Chung, Yazan F. Madanat, Prapti Patel, Syed M Rizvi, Praveen Ramakrishnan, Madhuri Vusirikala, Robert H. Collins, John Sweetenham, Jerry Shay, Ankit Kansagra

Blood (2021) 138 (Supplement 1): 4798.

https://doi.org/10.1182/blood-2021-153183

Published: 2021

Journal Articles

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

Blood (2018) 132 (25): 2639–2642.

https://doi.org/10.1182/blood-2018-07-861641

Published: 2018

Journal Articles

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

John Sweetenham, Jan Walewski, MDPhDProf, Auayporn P. Nademanee, MD, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, MD, Andy I Chen, MD PhD, Patrick Stiff, Simonetta Viviani, MD, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanova, MD, Anna Sureda, MD PhD, Dirk Huebner, Emily K Larsen, Naomi N Hunder, Craig H Moskowitz, MD

Blood (2015) 126 (23): 3172.

https://doi.org/10.1182/blood.V126.23.3172.3172

Published: 2015

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Similar Incidence Of Febrile Neutropenia With Same-Day Versus Subsequent Day G-CSF Administration In Non-Hodgkin Lymphoma Patients Receiving R-CHOP Chemotherapy

James Karol, MS, PA-C, Lisa Rybicki, MS, John Sweetenham, M.D., Mitchell R Smith, MD, PhD, Brian T. Hill, MD, PhD, Brad Pohlman, MD, Deepa Jagadeesh, MD, MPH, Elizabeth Gazdick, BS, MPH, Katie Fenner, BS, MS, Amanda L. Maggiotto, BS, CCRP, Robert M Dean, MD

Blood (2013) 122 (21): 4357.

https://doi.org/10.1182/blood.V122.21.4357.4357

Published: 2013

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, MD, John Sweetenham, MD, Ying Jiang, PhD, Sharon T Sullivan, PhD, Erik R Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2011) 118 (21): 2718.

https://doi.org/10.1182/blood.V118.21.2718.2718

Published: 2011

Journal Articles

Prognostic Significance of Bone Marrow Involvement At Diagnosis and At the Time of Autologous Stem Cell Transplantation for Lymphoma Relapse,

Aleksandr Lazaryan, MD, PhD, MPH, John Sweetenham, M.D., Lisa Rybicki, MS, Robert Dean, MD, Brad Pohlman, MD, Brian T. Hill, MD, PhD, Hien Duong, Ronald Sobecks, MD, Steven Andresen, DO, Shawnda Tench, Matt Kalaycio, MD, Brian J. Bolwell, MD, Edward A. Copelan, MD

Blood (2011) 118 (21): 4122.

https://doi.org/10.1182/blood.V118.21.4122.4122

Published: 2011

Journal Articles

Cell of Origin Determination in Diffuse Large B-Cell Lymphoma: Performance of Immunohistochemical (IHC) Algorithms and Ability to Predict Outcome

Brian T. Hill, MD, PhD, Angela M.B. Collie, M.D, Ph.D., Tomas Radivoyevitch, PhD, Eric D. Hsi, MD, John Sweetenham, M.D.

Blood (2011) 118 (21): 950.

https://doi.org/10.1182/blood.V118.21.950.950

Published: 2011

Journal Articles

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Robert Dean, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Amanda L. Maggiotto, BS, CCRP, Jennifer Bates, BS, CCRP, Stephen D. Smith, MD, Brian J. Bolwell, MD, John Sweetenham, MD

Blood (2011) 118 (21): 1621.

https://doi.org/10.1182/blood.V118.21.1621.1621

Published: 2011

Journal Articles

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff Sharman, John Sweetenham, Patrick B. Johnston, Julie M. Vose, Ann LaCasce, Julia Schaefer-Cutillo, Sven De Vos, Rajni Sinha, John P. Leonard, Larry D. Cripe, Stephanie A. Gregory, Michael P. Sterba, Ann M. Lowe, Ronald Levy, Margaret A. Shipp

Blood (2010) 115 (13): 2578–2585.

https://doi.org/10.1182/blood-2009-08-236471

Published: 2010

Journal Articles

Days of Pheresis Needed for Harvesting CD34+ Cells for Autologous Hematopoietic Stem Cell Transplantation Is Associated with Speed of Neutrophil Recovery and the Development of Secondary AML/MDS.

Shahbaz Malik, Brian J. Bolwell, Robert Dean, Ronald Sobecks, Matt Kalaycio, John Sweetenham, Brad Pohlman, Steve Andresen, Lisa Rybicki, Shawnda Tench, Priscilla Figueroa, MD, Edward Copelan

Blood (2009) 114 (22): 2151.

https://doi.org/10.1182/blood.V114.22.2151.2151

Published: 2009

Journal Articles

Etoposide Priming in Patients with Lymphoma Improves Mobilization without An Increased Risk of Secondary Hematologic Malignancies.

Anuj Mahindra, MD, Brian J. Bolwell, Robert Dean, Matt Kalaycio, Belinda Avalos, Lisa Rybicki, Shawnda Tench, Patrick Elder, Ronald Sobecks, John Sweetenham, Brad Pohlman, Steve Andresen, Steve Devine, Edward Copelan

Blood (2009) 114 (22): 2264.

https://doi.org/10.1182/blood.V114.22.2264.2264

Published: 2009

Journal Articles

Low Vitamin D Levels After Allogeneic Hematopoietic Stem Cell Transplant.

Lisa Sproat, MD, MSW, Brian J. Bolwell, Lisa Rybicki, Robert Dean, Ronald Sobecks, Brad Pohlman, Steven Andresen, John Sweetenham, Ed Copelan, Matt Kalaycio

Blood (2009) 114 (22): 3322.

https://doi.org/10.1182/blood.V114.22.3322.3322

Published: 2009

Journal Articles

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Alison J. Moskowitz, MD, John Sweetenham, MD, Brian J. Bolwell, MD, Jocelyn C Maragulia, Jill M Vanak, ACNP, Craig H Moskowitz, MD, Stephen Smith, MD

Blood (2009) 114 (22): 3413.

https://doi.org/10.1182/blood.V114.22.3413.3413

Published: 2009

Journal Articles

High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.

Stephen S. Smith, MD, Brian Bolwell, MD, Anjali Advani, MD, Steven Andresen, DO, Josephine Chan, Robert Dean, MD, Eric Hsi, MD, Matt Kalaycio, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Ronald Sobecks, MD, John Sweetenham, MD

Blood (2008) 112 (11): 1137.

https://doi.org/10.1182/blood.V112.11.1137.1137

Published: 2008

Journal Articles

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Jonathan W. Friedberg, MD, Jeff Sharman, Julia Schaefer-Cutillo, Patrick B. Johnston, Sven De Vos, MD, PhD, Ann LaCasce, MD, John P. Leonard, MD, Larry D. Cripe, MD, Rajni Sinha, MD, Stephanie A. Gregory, John Sweetenham, Julie M. Vose, MD, Ann M Lowe, MD, R. Levy, Margaret A. Shipp, MD

Blood (2008) 112 (11): 3.

https://doi.org/10.1182/blood.V112.11.3.3

Published: 2008

Journal Articles

Platelet Transfusion Requirement during ASCT for Lymphoma Is a Powerful Prognostic Variable.

Hien Duong, Lisa Rybicki, John Sweetenham, Brad Pohlman, Ronald Sobecks, Robert Dean, Edward Copelan, Steven Andresen, Stephen Smith, Shawnda Sungren, Josephine Chan, Brian Bolwell

Blood (2008) 112 (11): 3269.

https://doi.org/10.1182/blood.V112.11.3269.3269

Published: 2008

Journal Articles

Impact on Pulmonary Function of Pre-Transplant Radiotherapy in Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant (ASCT).

Christy Stotler, DO, Paul Elson, ScD, Brian Bolwell, MD, Matt Kalaycio, MD, Brad Pohlman, MD, Ronald Sobecks, MD, Robert Dean, MD, Steven Andresen, DO, Edward Copelan, MD, Josephine Chan, John Sweetenham, MD

Blood (2008) 112 (11): 3279.

https://doi.org/10.1182/blood.V112.11.3279.3279

Published: 2008

Journal Articles

Length of Stay among Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma:Predictive Factors and Prognostic Effect.

Anuj Mahindra, Brian Bolwell, Lisa Rybicki, Matt Kalaycio, Ronald Sobecks, Steve Andresen, Brad Pohlman, John Sweetenham, Edward Copelan, Robert Dean

Blood (2008) 112 (11): 2184.

https://doi.org/10.1182/blood.V112.11.2184.2184

Published: 2008

NARROW

Ascorbate Deficiency Is Associated with Severity of Cytokine Release Syndrome Following Therapy with Chimeric Antigen Receptor T-Cells

T-Cell Telomere Length As a Biomarker to Predict Outcome in Patients Receiving CAR-T Immunotherapy

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Similar Incidence Of Febrile Neutropenia With Same-Day Versus Subsequent Day G-CSF Administration In Non-Hodgkin Lymphoma Patients Receiving R-CHOP Chemotherapy

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Prognostic Significance of Bone Marrow Involvement At Diagnosis and At the Time of Autologous Stem Cell Transplantation for Lymphoma Relapse,

Cell of Origin Determination in Diffuse Large B-Cell Lymphoma: Performance of Immunohistochemical (IHC) Algorithms and Ability to Predict Outcome

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Days of Pheresis Needed for Harvesting CD34+ Cells for Autologous Hematopoietic Stem Cell Transplantation Is Associated with Speed of Neutrophil Recovery and the Development of Secondary AML/MDS.

Etoposide Priming in Patients with Lymphoma Improves Mobilization without An Increased Risk of Secondary Hematologic Malignancies.

Low Vitamin D Levels After Allogeneic Hematopoietic Stem Cell Transplant.

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Platelet Transfusion Requirement during ASCT for Lymphoma Is a Powerful Prognostic Variable.

Impact on Pulmonary Function of Pre-Transplant Radiotherapy in Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant (ASCT).

Length of Stay among Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma:Predictive Factors and Prognostic Effect.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only